Navigation Links
ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference
Date:9/3/2009

MARKHAM, ON, Sept. 3 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, today announced that it is scheduled to make an investor presentation at the Rodman Renshaw Annual Global Investment Conference at 2:25 pm EDT on Friday, September 11, 2009. The conference will be held at the New York Palace Hotel, September 9-11, 2009.

AlphaRx will make its presentation in the Spellman Salon (5th Floor) and a live webcast of the presentation will be available via a link provided at http://www.wsw.com/webcast/rrshq15/alrx . An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. For more information, please visit www.AlphaRx.com.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company's operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx To Present at 47th Annual ICAAC
2. AlphaRx Announces Debt Conversion
3. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
4. AlphaRx CEO Accumulates More Company Shares
5. AlphaRxs Indaflex(TM) Continues its Clinical Development
6. AlphaRx Provides Corporate and Development Update
7. AlphaRx Signs Cooperative Research and Development Agreement with US Army
8. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
9. AlphaRx Shareholder Update
10. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
11. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Petersburg, Fla. (PRWEB) , ... December 05, 2016 , ... ... concussions have on the growing brains of young athletes. Over the course of three ... the head through unique mouth guards. The mouth guards, equipped with special sensors, will ...
(Date:12/5/2016)... NY (PRWEB) , ... December 05, 2016 , ... ... to use a patent-pending blend of L-Citrulline and glutathione to enhance production of ... a combination that studies have shown to produce NO twice as effectively and ...
(Date:12/5/2016)... ... December 05, 2016 , ... Eating disorders ... goal of Castlewood Treatment Centers has always been to promote the power of ... people as possible. In that spirit, Castlewood has announced two new hires, both ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Partners ("GPP") portfolio company, today announced it has acquired the assets of ... was previously a subsidiary of Chiltern International and focuses on clinical trial ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... India , December 5, 2016 According ... by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free ... published by MarketsandMarkets, the market is projected to reach USD 779.8 ... a CAGR of 13.5% during the forecast period of 2016 to ... ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)...  CVS Health, the nation,s largest pharmacy innovation company, ... of 100 percent on the Corporate Equality Index (CEI) ... annual national benchmarking survey and report on corporate policies ... Human Rights Campaign Foundation. "Our company,s ... customers and suppliers bring to CVS Health," said ...
Breaking Medicine Technology: